ID | 1024 |
Name of the vaccine | Quinvaxem inj. |
Microbe | Bacteria |
Disease name | Diphtheria |
Name of bacteria | Corynebacterium diphtheriae |
Type of vaccine | Subunit |
Nucleic acid content | DNA |
Age | From 6 weeks |
Description of the vaccine | DTwP-HepB-Hib vaccine. |
Name of the manufacturer | Berna Biotech Korea Corp. |
Name of the manufacturing country | Korea |
Year of manufacture | 2006 |
Clinical Phase status | Approved |
Bacterial strain | Gram-positive bacillus. |
Efficacy | Predefined protective antibody level was 99% diphtheria. |
Vaccine formulation | Homogeneous liquid |
Dosage | Primary vaccination : 3 doses of 0.5 mL and one booster dose of 0.5 mL in 15-18 months. |
Mechanism of action | Immunostimulants |
Route of administration | Intramuscular |
Indications | Primary and booster immunisation against diphtheria, tetanus, pertussis, hepatitis B, and invasive illness caused by H. influenzae type b. |
Export | Distributed by: GlaxoSmithKline Pharmaceuticals Limited, India |
Approval | WHO pre-qualified |
Adjuvant | Aluminium phosphate |
Repurposing | For Hib, tetanus, pertussis and hepatitis B recombinant. |
Side effects of vaccine | Temporary swelling, tenderness and redness together with fever, feeding disorders, sleepiness, irritability. |
Post vaccination | NA |
Dose type | Both |
Interspecies transfer | NA |
PubMed identifier | 22889824 |
Clinical trial number | NA |
Reference | https://india-pharma.gsk.com/media/787410/quinvaxem-with-gsk-as-distributor.pdf |
Other name | NA |
Additional Links | https://www.who.int/immunization_standards/vaccine_quality/pq_283_dtphepbhib_1dose_cPAD_Crucell_Korea_PI.pdf
|